High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar-Reference-Cited by-同舟云学术

High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar

Published:2019-06-10 Issue:10 Volume:26 Page:1186-1199
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Hlaing Naomi Khaing Than¹,Nangia Gayatri²,Tun Kyaw Thet¹,Lin Sithu¹,Maung Moe Zaw¹,Myint Khin Thuzar¹,Kyaw A. Mi Mi¹,Maung Soe Thiha³,Sein Win Sithu³,Bwa Aung Hlaing³,Loza Bao‐Li²,Win Khin Maung³,Reddy K. Rajender²^ORCID

Affiliation:

1. Mandalay General Hospital Mandalay Myanmar

2. University of Pennsylvania Philadelphia Pennsylvania

3. Yangon GI and Liver Center Yangon Myanmar

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13133

Reference29 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

2. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection

3. Global epidemiology and genotype distribution of the hepatitis C virus infection

4. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country

5. Hepatitis C virus genotype distribution in Myanmar: Predominance of genotype 6 and existence of new genotype 6 subtype

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong;BMC Gastroenterology;2024-01-25

2. Epidemiological characteristics and real‐world treatment outcomes of hepatitis C among HIV/HCV co‐infected patients in Myanmar: A prospective cohort study;Health Science Reports;2023-02

3. Real‐world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes;JGH Open;2022-11-29

4. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis;World Journal of Hepatology;2022-06-27

5. Outcomes of the CT2 study: A ‘one‐stop‐shop’ for community‐based hepatitis C testing and treatment in Yangon, Myanmar;Liver International;2021-07-10